CUTANEOUS LUPUS ERYTHEMATOSUS
Clinical trials for CUTANEOUS LUPUS ERYTHEMATOSUS explained in plain language.
Never miss a new study
Get alerted when new CUTANEOUS LUPUS ERYTHEMATOSUS trials appear
Sign up with your email to follow new studies for CUTANEOUS LUPUS ERYTHEMATOSUS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New lupus skin rash pill enters final testing phase
Disease control Not yet recruitingThis study aims to see if a new pill called enpatoran can safely reduce skin rashes and symptoms in people with lupus. About 202 participants with active lupus skin disease will take either the drug or a placebo pill for 24 weeks while continuing their standard lupus medications.…
Matched conditions: CUTANEOUS LUPUS ERYTHEMATOSUS
Phase: PHASE3 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
New pill aims to tame painful lupus skin flares
Disease control Not yet recruitingThis study is testing whether a pill called enpatoran can safely reduce active skin rashes in people with lupus. About 202 participants with moderate-to-severe lupus skin symptoms will take either enpatoran or a placebo pill for 24 weeks, while continuing their standard lupus med…
Matched conditions: CUTANEOUS LUPUS ERYTHEMATOSUS
Phase: PHASE3 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Mar 19, 2026 14:56 UTC
-
First human test for potential lupus treatment begins
Knowledge-focused Not yet recruitingThis is a very early-stage study to check the safety of a new drug called ACT100, which is being developed for lupus. It will be tested in 48 healthy volunteers to see how their bodies react to it and how the drug moves through their system. The main goal is to find a safe dose a…
Matched conditions: CUTANEOUS LUPUS ERYTHEMATOSUS
Phase: PHASE1 • Sponsor: Xiamen Amoytop Biotech Co., Ltd. • Aim: Knowledge-focused
Last updated Apr 02, 2026 05:41 UTC